Literature DB >> 20592227

Alpha2-adrenergic receptors and their core involvement in the process of axonal growth in retinal explants.

Verena Prokosch1, Lambros Panagis, Gerd Fabian Volk, Caterina Dermon, Solon Thanos.   

Abstract

PURPOSE: To determine the patterns of α2-adrenergic receptor (α2-AR) subtype expression in normal and degenerated retinas and to analyze the response of these receptors to the α2-AR agonist brimonidine tartrate (BT).
METHODS: The binding characteristics of α2-ARs in the retina were evaluated in experimental and matching sham groups by in vitro quantitative autoradiographic saturation with [(3)H]-clonidine. Retinal explants from juvenile and adult rats with either elevated intraocular pressure or after optic nerve crush (ONC) were cultured with BT over 96 hours in vitro to analyze the effects of BT on axonal growth by videomicroscopy and axon counting. Changes in retinal protein expression by BT were monitored by two-dimensional gel electrophoresis (2D-PAGE) and matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS).
RESULTS: The total number of α2-ARs in the retina increased significantly after ONC compared with the sham group. BT supported axonal growth in the juvenile, glaucomatous, and injured retinas (P < 0.004) most effectively at a concentration of 0.001 mg/mL, without influencing the axonal growth rate. Immediate supplementation of BT was more effective than delayed supplementation (P < 0.001). Proteomic analysis revealed treatment-specific expression patterns of glial fibrillary acidic protein (GFAP), glucose-related protein (GRP)58, platelet-activating factor (PAF), and laminin-binding protein (LBP).
CONCLUSIONS: These data are the first to show differences in α2-AR expression in normal and degenerated retinas. BT supports neuronal growth in cultured retinal pieces, suggesting that α2-ARs play a role in retinal metabolism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20592227     DOI: 10.1167/iovs.09-4835

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  9 in total

Review 1.  A decade of proteomics studies of glaucomatous neurodegeneration.

Authors:  Gülgün Tezel
Journal:  Proteomics Clin Appl       Date:  2014-02-16       Impact factor: 3.494

2.  Gαz regulates BDNF-induction of axon growth in cortical neurons.

Authors:  Rainbo Hultman; Udhaya Kumari; Nadine Michel; Patrick J Casey
Journal:  Mol Cell Neurosci       Date:  2013-12-07       Impact factor: 4.314

Review 3.  A proteomics view of the molecular mechanisms and biomarkers of glaucomatous neurodegeneration.

Authors:  Gülgün Tezel
Journal:  Prog Retin Eye Res       Date:  2013-02-05       Impact factor: 21.198

4.  Axonal protection by brimonidine with modulation of p62 expression in TNF-induced optic nerve degeneration.

Authors:  Yasushi Kitaoka; Kaori Kojima; Yasunari Munemasa; Kana Sase; Hitoshi Takagi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-12       Impact factor: 3.117

Review 5.  Neuroprotection in Glaucoma.

Authors:  Azadeh Doozandeh; Shahin Yazdani
Journal:  J Ophthalmic Vis Res       Date:  2016 Apr-Jun

6.  Non-amyloidogenic effects of α2 adrenergic agonists: implications for brimonidine-mediated neuroprotection.

Authors:  Shereen Nizari; Li Guo; Benjamin M Davis; Eduardo M Normando; Joana Galvao; Lisa A Turner; Mukhtar Bizrah; Mohammad Dehabadi; Kailin Tian; M Francesca Cordeiro
Journal:  Cell Death Dis       Date:  2016-12-08       Impact factor: 8.469

Review 7.  The Role of Adrenoceptors in the Retina.

Authors:  Yue Ruan; Tobias Böhmer; Subao Jiang; Adrian Gericke
Journal:  Cells       Date:  2020-12-03       Impact factor: 6.600

8.  Polydopamine nanoparticles attenuate retina ganglion cell degeneration and restore visual function after optic nerve injury.

Authors:  Xiaotong Lou; Yuanyuan Hu; Hong Zhang; Jia Liu; Yin Zhao
Journal:  J Nanobiotechnology       Date:  2021-12-20       Impact factor: 10.435

9.  Will Cannabigerol Trigger Neuroregeneration after a Spinal Cord Injury? An In Vitro Answer from NSC-34 Scratch-Injured Cells Transcriptome.

Authors:  Andrea Valeri; Luigi Chiricosta; Agnese Gugliandolo; Federica Pollastro; Emanuela Mazzon
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.